Trump Administration Continues Drug Pricing Deals as GLP-1 Coverage Expansion Hits Roadblocks
nashnova research
CMS chief Mehmet Oz says the administration has struck over twenty voluntary drug-pricing deals, but GLP-1 weight-loss drug coverage is stalling on both the Medicaid and Medicare fronts — leaving Eli Lilly's and Novo Nordisk's policy upside in doubt.
How were these twenty-plus deals structured?
Drugmakers agreed to lower prices charged to public health programs and benchmark new-drug pricing to other developed nations — in exchange for tariff exemptions.
This means → it is not a government-imposed price cut but a swap: companies give up margin to protect import-cost advantages.
Some firms also offer discounted prices directly to consumers on a Trump-branded website, but critics note insured patients see limited real savings.
Why is GLP-1 coverage stuck?
Under Medicaid — the program for low-income and disabled Americans — CMS is pushing states to cover GLP-1 drugs at the negotiated lower price, but progress has stalled.
State governors worry the drugs will strain state budgets and are seeking to narrow who qualifies for coverage.
In plain terms = the federal government negotiated a discount, but states foot the bill — and governors still find it too expensive, so they want to cover fewer people.
What about Medicare's $50-a-month plan?
Medicare's $50-per-month GLP-1 coverage plan is reaching fewer seniors than initially expected.
Two reasons: commercial insurers have not joined the CMS pilot, and seniors with other qualifying conditions cannot access the $50 price — they often pay more.
This means → the $50 plan looks affordable on paper, but eligible patients are blocked by two barriers — insurers sitting out and a narrow list of qualifying conditions.
What does this mean for Eli Lilly and Novo Nordisk?
Whether GLP-1 coverage can meaningfully expand to a broader population is the key test of whether Eli Lilly's and Novo Nordisk's policy tailwinds translate into volume.
This reflects a recurring gap: signing a pricing deal is not the same as unlocking demand — every step from federal agreement to state rollout to insurer participation can stall.
In plain terms = the "last mile" of the policy upside remains unfinished, and both companies' GLP-1 volume expectations deserve a question mark.
市场有风险，内容仅供研究参考，不构成投资建议。